Events & Groups:
Clearview News Wire
Copyright © 2007 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
Takeda cancer drug slows tumor growth in mice
Last Updated: 2009-04-08 16:12:34 -0400 (Reuters Health)April 9, 2009
By Julie SteenhuysenCHICAGO (Reuters) - An experimental cancer drug made by Takeda Pharmaceutical Co showed signs of slowing tumors growth in mice and has advanced to early human trials, company researchers said Wednesday.
The drug, developed by Takeda's recently acquired Millennium Pharmaceuticals unit, suppressed tumor cell growth in human lung tissue that had been transplanted into mice, the company reported in the journal Nature.
Teresa Soucy, a Millennium researcher in Massachusetts who led the study, said her team has tested the drug in several different types of tumors in mice.
"We've always seen at least tumor growth inhibition, and in some cases, regression -- in some cases they get smaller," Soucy said in a telephone interview.
The drug, called MLN4924, is similar to the company's blood cancer drug Velcade but targets a different enzyme called the NEDD8-Activating enzyme, which regulates proteins cancer cells need to grow and survive.
Soucy said the new drug works by blocking an early step in the regulation of how certain proteins are broken down.
"We've blocked their degradation," she said, which is causing DNA to "oversynthesize" or replicate.
"It can't stop. What ends up happening is the DNA gets damaged and the cells die. It was an unexpected finding," she said.
Soucy said Velcade works in this same basic pathway, but at a later stage. She said the new drug may be more selective than Velcade and could have fewer unwanted side effects, but that has to be proven.
"With Velcade, it does have neuropathy. People feel tingling in their fingers when they take it," she said.
She said one potential reason for that is the buildup of unwanted proteins in brain cells. Soucy said the new compound theoretically could address some of these issues.
Takeda is currently studying the molecule in several early clinical trials in humans in solid tumors and blood cancers.
"The compound is very well tolerated in mice. We just have to see in humans. It has potentially different clinical efficacy. We just don't know yet," Soucy said.
Johnson & Johnson co-develops Velcade, which is known generically as bortezomib.
Other Articles:
- February 16, 2010
- Occupation a key factor in men's lung cancer risk
- February 15, 2010
- Pricey scans have no impact in breast cancer: study
- February 11, 2010
- Researchers find sex-specific lung cancer genes
- February 10, 2010
- Even third-hand smoke carries carcinogens
- February 8, 2010
- Men who eat soy may have lower lung cancer risk
- February 8, 2010
- Well-being similar after total or partial hysterectomy
- February 5, 2010
- Medicare cuts damage cancer care, group finds
- February 5, 2010
- Hormone replacement tied to lower colon cancer risk
- February 2, 2010
- Study weighs benefits of transplants for leukemia
- February 1, 2010
- Cancer study backs Herceptin with chemo
- January 26, 2010
- Alternative prostate cancer vaccine shows promise
- January 25, 2010
- Project seeks genetic basis of childhood cancer
- January 25, 2010
- Gene discovery may help guide breast cancer care
- January 20, 2010
- Deadly brain cancer not a single disease
- January 20, 2010
- Age important in hereditary pancreatic cancer risk
- January 19, 2010
- Higher vitamin D levels linked to risk for basal cell carcinoma